BioHiTech Global Reports Second Quarter 2021 Financial Results With Record Revenue
BioHiTech Global, Inc. (NASDAQ: BHTG) reported financial results for Q2 2021, revealing total revenues of $3.5 million, a 14% increase from Q1 2021, and a 171% surge from Q2 2020. This marks the third consecutive quarter of record revenue since going public in 2015. The company's Digester and Corporate line revenue soared over 700% year-over-year due to significant sales to Carnival Corporation. However, operational losses totaled $3.1 million, with unrestricted cash at $2.3 million as of June 30, 2021.
- Total revenue grew 171% year-over-year to $3.5 million.
- Digester and Corporate line revenue increased 700% year-over-year due to Carnival Corporation sales.
- Third consecutive quarter of record revenues since going public.
- Consolidated net loss of $3.1 million for the quarter.
- Operational losses reached $2.0 million.
- HEBioT line revenue decreased 58% year-over-year due to ongoing maintenance shutdowns.
CHESTNUT RIDGE, N.Y., Aug. 9, 2021 /PRNewswire/ -- BioHiTech Global, Inc. ("BioHiTech" or the "Company") (NASDAQ: BHTG), a sustainable technology and services company, today announces financial results for its fiscal second quarter ending June 30, 2021.
Q2 2021 Financial Highlights
- The Company continued its revenue growth in the quarter ended June 30, 2021, with total revenues of
$3.5 million increasing14% over the first quarter of 2021,38% over the fourth quarter of 2020 and171% over the comparative second quarter of 2020. Total revenues of$3.5 million mark the third consecutive quarter of record revenue since the Company went public in 2015.
- Second quarter 2021 Digester and Corporate line of business revenues increased by over
700% from$381,000 to$3,078,000 versus Q2 2020, driven by Carnival Cruise Lines equipment sales.
Corporate Highlights Q2 2021
- May 2021 - BioHiTech received additional purchase orders totaling approximately
$2.3 million for the Company's Revolution Series™ Digesters for 16 additional ships from Carnival Corporation.
- May 2021 - West Virginia signed Senate Bill 368 into law, effectively eliminating solid waste assessment fees for mixed waste processing and resource recovery facilities, such as BioHiTech's Martinsburg, WV HEBioT Plant, helping to make renewable energy a more attractive investment and making the development of renewable facilities economically viable.
- June 2021 - BioHiTech entered into a project management services agreement with Lone Cypress Energy Services to evaluate and develop new High-Efficiency Biological Treatment projects. The two companies are exploring additional uses of Solid Recovered Fuel as well as other potential fuels that could be developed.
Tony Fuller, BioHiTech's CEO commented: "Our second quarter 2021 performance demonstrates consistent execution across both our complementary waste technology solutions. Revenue of
"Our complementary waste technology solutions are but two of many, both deployed and those yet to be developed or deployed, in the broad spectrum of solutions. Our vision is to drive sustainability and lead improved environmental outcomes, reduce carbon emissions, reduce landfill usage, and create alternative fuels from that which had been destined for a landfill. Action and deep commitment are needed to reverse damaging impacts of climate change. We are more driven than ever to provide real-world solutions that make immediate impacts.
"The continued expansion of our relationship with Carnival Corporation is encouraging as we support their commitment to drive sustainability through environmentally friendly food waste disposal. Moreover, our digester data analytics platform provides real-time waste transparency which promote changes in supply chain management, purchasing, handling, and food preparation, reducing food waste at its source. We are actively engaged in opportunities across not only the maritime sector but also retail, healthcare, government, hospitality, food service, and others, which we hope to convert into new client wins in the coming quarters.
"We are keenly focused on driving client utilization of our EPA-recognized Solid Recovered Fuel (SRF) which we produce at our Martinsburg, WV HEBioT plant. This facility is capable of processing 110,000 tons of municipal solid waste annually while producing 50,000 – 60,000 tons of SRF for use by cement manufacturers and others as a replacement for coal. We have improved plant operations throughout the quarter as our investment in solving past inefficiencies and curing mechanical and operational issues sets the stage for reliability in process and consistency in production. Maintenance and repairs shutdowns at our SRF customer led to weaker than anticipated performance. Those issues have been largely resolved, and we expect more consistent production, delivery, and sales growth in the coming quarters.
"With the passage of West Virginia's Senate Bill 368 into law in May 2021, the state effectively eliminated solid waste assessment fees for mixed waste processing and resource recovery facilities such as ours in Martinsburg, WV. This is most promising for our expansion plans into additional communities within the state. We expect this to drive positive and near-term environmental impact through landfill diversion, transportation, and fuel conservation. This bodes well for BioHiTech and our stakeholders as we forge ahead to make renewable energy the norm and leverage the opportunities offered by the state's actions to make the development of additional renewable facilities economically more attractive.
"To those ends, in June, we entered into a project management services agreement with Lone Cypress Energy Services, a firm specializing in the development of waste-to-energy solutions. Together we are evaluating and developing new plans for HEBioT projects. We are also exploring additional uses of our SRF. This includes additional projects in connection with hydrogen and other renewable technologies including the use of our feedstock for gasification and bioplastics.
"In summary, we are executing on our growth plans, our corporate objectives and our overarching goals of 2021. We continue to drive record revenue. We are smartly leveraging our expense structure. We have significantly improved plant operations. We have engaged with and learned from our shareholders as we have shared our story. And we have strengthened our team and executed at record levels. As always, I look forward to elaborating more on our progress in our earnings conference call later this afternoon and throughout the quarter," concluded Mr. Fuller.
Financial Results for the Quarter ended June 30, 2021
The Company continued its revenue growth in the quarter ended June 30, 2021, with total revenues of
The overall contribution (revenues, less direct costs) increased to
Selling, general and administrative expenses as a percentage of revenues increased to
The loss from operations as a percentage of revenue decreased to
The Company continues to achieve growth in the Digester and Corporate line of business that has been driven by sales to Carnival Corporation such that the second quarter revenues increased in the second quarter of 2021 by
The revenues of the HEBioT line have continued to be hampered by maintenance and repairs shutdowns at its SRF customer resulting in a
For the three months ended June 30, 2021, the Company had a consolidated loss attributable to the parent of
At June 30, 2021, unrestricted cash was
Conference Call to be held Monday, August 9, 2021, at 4:30 PM ET
Mr. Tony Fuller, Chief Executive Officer of BioHiTech, will host a conference call on Monday, August 9, 2021, at 4:30 p.m. EDT to discuss the Company's financial results for the second quarter ended June 30, 2021. Also joining Mr. Fuller on the call from management will be Brian Essman, Chief Financial Officer. Following management's formal remarks, there will be a live question-and-answer session.
Participants are asked to pre-register for the call via the following link:
https://dpregister.com/sreg/10159374/ec2df07762
Please note that registered participants will receive their dial-in number upon registration and will dial directly into the call without delay. Those without Internet access or who are unable to pre-register may dial in by calling 1-866-652-5200 (domestic) or 1-412-317-6060 (international). All callers should dial in approximately 10 minutes prior to the scheduled start time and ask to be joined into the BioHiTech Global call.
The conference call will be available through a live webcast found here.
It will also be broadcast live through the Company's website with the following link:
http://investors.biohitechglobal.com/events-and-webcasts
A webcast replay of the call will be available approximately one hour after the end of the call through November 9, 2021. The webcast replay can be accessed through the above links or by calling 1-877-344-7529 (domestic) or 1-412-317-0088 (international) and using access code 10159374. A telephonic replay of the call will be available through August 23, 2021.
About BioHiTech Global
BioHiTech Global, Inc. (NASDAQ: BHTG), is a technology services company focused on providing cost-effective solutions that improve environmental outcomes. Our technologies for waste management include the patented processing of municipal solid waste into a valuable renewable fuel, biological disposal of food waste on-site, and proprietary real-time data analytics tools to reduce food waste generation. When used individually or in combination, our solutions lower the carbon footprint associated with waste transportation and can reduce or virtually eliminate landfill usage. Our unique solutions enable businesses and municipalities of all sizes to solve everyday problems in a smarter and more cost-effective way while reducing their impact on the environment. For more information, please visit www.biohitech.com.
Forward Looking Statements
Statements in this document contain certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, as amended. These statements, including statements about the estimated future results, contract value, additional purchase orders or deliveries, and the ability of the Company's products to improve environmental outcomes and achieve corporate sustainability goals, are based on many assumptions and estimates and are not guarantees of future performance. These statements may involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of BioHiTech Global, Inc. to be materially different from future results, performance or achievements expressed or implied by such forward-looking statements. BioHiTech Global, Inc. assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. Our actual results may differ materially from the results anticipated in these forward-looking statements due to a variety of factors, including, without limitation those set forth as "Risk Factors" in our filings with the Securities and Exchange Commission ("SEC"). There may be other factors not mentioned above or included in the BioHiTech's SEC filings that may cause actual results to differ materially from those projected in any forward-looking statement. BioHiTech Global, Inc. assumes no obligation to update any forward-looking statements as a result of new information, future events or developments, except as required by securities laws.
Company Contact:
BioHiTech Global, Inc.
Lisa Giovannielli
VP, Corporate Communications
O: 888.876.9300
E: lgiovannielli@biohitech.com
Investors:
ir@biohitech.com
Financial Tables Follow
BioHiTech Global, Inc. and Subsidiaries | ||||||||||||
Condensed Consolidated Statements of | ||||||||||||
Operations and Comprehensive Loss (Unaudited) | ||||||||||||
Three Months Ended | Six Months Ended | |||||||||||
June 30, | June 30, | |||||||||||
2021 | 2020 | 2021 | 2020 | |||||||||
Revenue | ||||||||||||
Equipment sales | $ | 2,630,993 | $ | — | $ | 4,897,506 | $ | 323,116 | ||||
Rental, service and maintenance | 447,427 | 356,033 | 868,656 | 827,126 | ||||||||
HEBioT | 376,554 | 892,899 | 729,102 | 1,383,031 | ||||||||
Management advisory and other fees (related party) | — | 25,000 | — | 100,000 | ||||||||
Total revenue | 3,454,974 | 1,273,932 | 6,495,264 | 2,633,273 | ||||||||
Operating expenses | ||||||||||||
Equipment sales | 1,806,324 | — | 3,042,340 | 146,404 | ||||||||
Rental, service and maintenance | 297,463 | 151,695 | 553,172 | 412,530 | ||||||||
HEBioT processing | 879,491 | 1,020,277 | 1,556,768 | 1,832,704 | ||||||||
Selling, general and administrative | 2,012,397 | 1,897,442 | 3,658,354 | 3,815,865 | ||||||||
Depreciation and amortization | 501,098 | 569,764 | 1,002,931 | 1,184,966 | ||||||||
Total operating expenses | 5,496,773 | 3,639,178 | 9,813,565 | 7,392,469 | ||||||||
Loss from operations | (2,041,799) | (2,365,246) | (3,318,301) | (4,759,196) | ||||||||
Other expenses | ||||||||||||
Interest (income) | (123) | (5,355) | (310) | (17,622) | ||||||||
Interest expense | 1,031,011 | 1,025,319 | 2,059,416 | 2,037,610 | ||||||||
Loss from unconsolidated entity | 2,746 | — | 32,749 | — | ||||||||
Total other expenses | 1,033,634 | 1,019,964 | 2,091,855 | 2,019,988 | ||||||||
Net loss | (3,075,433) | (3,385,210) | (5,410,156) | (6,779,184) | ||||||||
Net loss attributable to non-controlling interests | (695,229) | (720,329) | (1,395,739) | (1,543,006) | ||||||||
Net loss attributable to Parent | (2,380,204) | (2,664,881) | (4,014,417) | (5,236,178) | ||||||||
Other comprehensive income | ||||||||||||
Foreign currency translation adjustment | (5,369) | (1,437) | (16,044) | (30,136) | ||||||||
Comprehensive loss | $ | (2,385,573) | $ | (2,666,318) | $ | (4,030,461) | $ | (5,266,314) | ||||
Net loss attributable to Parent | $ | (2,380,204) | $ | (2,664,881) | $ | (4,014,417) | $ | (5,236,178) | ||||
Less – preferred stock dividends | (175,169) | (204,941) | (358,024) | (382,313) | ||||||||
Net loss – common shareholders | (2,555,373) | (2,869,822) | (4,372,441) | (5,618,491) | ||||||||
Net loss per common share - basic and diluted | $ | (0.09) | $ | (0.16) | $ | (0.17) | $ | (0.32) | ||||
Weighted average number of common shares outstanding - basic and diluted | 28,259,677 | 17,437,068 | 26,301,029 | 17,406,788 | ||||||||
BioHiTech Global, Inc. and Subsidiaries | ||||||
Condensed Consolidated Balance Sheets | ||||||
June 30, | ||||||
2021 | December 31, | |||||
(Unaudited) | 2020 | |||||
Assets | ||||||
Current Assets | ||||||
Cash | $ | 2,279,060 | $ | 2,403,859 | ||
Restricted cash | 3,808,751 | 1,884,691 | ||||
Accounts receivable, net of allowance for doubtful accounts of | 1,847,746 | 1,574,047 | ||||
Inventory | 1,381,338 | 695,110 | ||||
Prepaid expenses and other current assets | 259,374 | 184,274 | ||||
Total Current Assets | 9,576,269 | 6,741,981 | ||||
Restricted cash | 2,603,440 | 2,607,945 | ||||
Equipment on operating leases, net | 1,158,558 | 1,311,755 | ||||
HEBioT facility, equipment, fixtures and vehicles, net | 35,330,255 | 35,946,225 | ||||
License and capitalized MBT facility development costs | 8,037,859 | 8,072,471 | ||||
Other assets | 1,924,203 | 2,006,048 | ||||
Total Assets | $ | 58,630,584 | $ | 56,686,425 | ||
Liabilities and Stockholders' Equity | ||||||
Current Liabilities | ||||||
Accounts payable | $ | 2,720,443 | $ | 2,492,606 | ||
Accrued expenses and liabilities | 1,332,718 | 2,515,724 | ||||
Accrued interest payable | 1,344,293 | 1,279,018 | ||||
Customer deposits | 2,026,555 | 1,802,725 | ||||
Current portion of notes, bonds, debts and borrowings | 10,992,863 | 10,120,457 | ||||
Deferred revenue | 268,871 | 138,961 | ||||
Total Current Liabilities | 18,685,743 | 18,349,491 | ||||
Non-current portion of notes, bonds, debts and borrowings | 29,352,846 | 29,645,227 | ||||
Accrued interest (related party) | 1,896,467 | 1,807,857 | ||||
Non-current lease liabilities | 1,157,414 | 1,216,861 | ||||
Liabilities to non-controlling interests to be settled in subsidiary membership units | — | 1,585,812 | ||||
Total Liabilities | 51,092,470 | 52,605,248 | ||||
Series A redeemable convertible preferred stock, 333,401 shares designated and issued, and 95,312 and 125,312 outstanding as of June 30, 2021 and December 31, 2020, respectively | 476,560 | 626,553 | ||||
Commitments and Contingencies | ||||||
Stockholders' Equity | ||||||
Preferred stock, | 5,057,942 | 6,621,576 | ||||
Common stock, | 2,835 | 2,334 | ||||
Additional paid in capital | 69,682,816 | 60,253,664 | ||||
Accumulated deficit | (68,852,919) | (64,419,802) | ||||
Accumulated other comprehensive (loss) | (159,858) | (143,814) | ||||
Stockholders' equity attributable to Parent | 5,730,816 | 2,313,958 | ||||
Stockholders' equity attributable to non-controlling interests | 1,330,738 | 1,140,666 | ||||
Total Stockholders' Equity | 7,061,554 | 3,454,624 | ||||
Total Liabilities and Stockholders' Equity | $ | 58,630,584 | $ | 56,686,425 | ||
BioHiTech Global, Inc. and Subsidiaries | ||||||
Condensed Consolidated Statements of Cash Flows (Unaudited) | ||||||
Six Months Ended | ||||||
June 30, | ||||||
2021 | 2020 | |||||
Cash flows from operating activities: | ||||||
Net loss | $ | (5,410,156) | $ | (6,779,184) | ||
Adjustments to reconcile net loss to net cash used in operations: | ||||||
Depreciation and amortization | 1,002,931 | 1,184,966 | ||||
Amortization of operating lease right of use assets | 38,996 | 53,552 | ||||
Provision for bad debts | 30,000 | 61,119 | ||||
Share based employee and vendor compensation | 345,488 | 707,653 | ||||
Interest resulting from amortization of financing costs and discounts | 219,437 | 265,776 | ||||
Loss from unconsolidated entity | 32,749 | — | ||||
Changes in operating assets and liabilities | (519,750) | 593,507 | ||||
Net cash used in operating activities | (4,260,305) | (3,912,611) | ||||
Cash flow from investing activities: | ||||||
Purchases of facility, equipment, fixtures and vehicles | (184,914) | (50,731) | ||||
Refund of deposit | — | 5,000 | ||||
MBT facility development costs incurred | (28,388) | (36,996) | ||||
Net cash used in investing activities | (213,302) | (82,727) | ||||
Cash flows from financing activities: | ||||||
Proceeds from the sales of common stock | 6,895,618 | — | ||||
Proceeds from the sale of Series F convertible preferred stock units | — | 1,560,450 | ||||
Proceeds from Payroll Protection Program Loan | — | 421,300 | ||||
Repayment of Senior secured note | (625,000) | |||||
Repayments of long-term debt | (2,163) | (2,496) | ||||
Related party advances, net | — | 725,000 | ||||
Net cash provided by financing activities | 6,268,455 | 2,704,254 | ||||
Effect of exchange rate on cash (restricted and unrestricted) | (92) | (20,208) | ||||
Net change in cash (restricted and unrestricted) | 1,794,756 | (1,311,292) | ||||
Cash - beginning of period (restricted and unrestricted) | 6,896,495 | 5,536,952 | ||||
Cash - end of period (restricted and unrestricted) | $ | 8,691,251 | $ | 4,225,660 | ||
Supplementary cash flow information (cash paid during the periods): | ||||||
Interest | $ | 1,524,097 | $ | 1,491,867 | ||
Income taxes | — | — | ||||
Supplementary Disclosure of Non-Cash Investing and Financing Activities: | ||||||
Transfer of inventory to leased equipment | $ | 54,000 | $ | 67,604 | ||
Acquisition of right of use leased asset and creation of lease liability | — | 412,647 | ||||
Accrual of Series A preferred stock dividends | 24,821 | 35,109 | ||||
Payment of Series A preferred stock dividends in common stock | 79,181 | 25,000 | ||||
Payment of preferred stock dividends in common stock | 390,460 | — | ||||
Issuance of subsidiary membership interest in exchange for liabilities due non-controlling interest entity | 1,918,947 | — | ||||
Exchange of subsidiary non-controlling interest in exchange for liabilities owed Company by non-controlling interest entity | 333,135 | — | ||||
Reconciliation of Cash and Restricted Cash: | ||||||
Cash | $ | 2,279,060 | $ | 342,182 | ||
Restricted cash (current) | 3,808,751 | 1,237,097 | ||||
Restricted cash (non-current) | 2,603,440 | 2,646,381 | ||||
Total cash and restricted cash at the end of the period | $ | 8,691,251 | $ | 4,225,660 | ||
View original content to download multimedia:https://www.prnewswire.com/news-releases/biohitech-global-reports-second-quarter-2021-financial-results-with-record-revenue-301351338.html
SOURCE BioHiTech Global, Inc.
FAQ
What were BioHiTech's Q2 2021 revenue figures?
How did BioHiTech perform compared to the previous quarter?
What is the current cash position of BioHiTech as of June 30, 2021?
What was the impact of Carnival Corporation on BioHiTech's revenues?
What are the projected challenges for BioHiTech in the coming quarters?
